Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig J Kutz

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The Journal of Emergency Medicine|June 7, 2021
An Unexpected "Delivery" in the Emergency Department: Hydatidiform MoleCraig J Kutz, Allyson Kreshak
Aerospace Medicine and Human Performance|July 11, 2025
Expanding Ketamine Application for Treatment of Acute Suicidality in Long-Duration SpaceflightCraig J Kutz, Amit M Mistry, Charles H Dukes
Emergency Medicine Clinics of North America|June 26, 2024
Spaceflight EnvironmentSamantha A King, Craig J Kutz, Natacha G Chough
Medchemcomm|January 13, 2015
3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitorsCraig J Kutz, Steven L Holshouser, Ethan A Marrow, et al.
Frontiers in Neurology|July 16, 2015
Histone Deacetylases Exert Class-Specific Roles in Conditioning the Brain and Heart Against Acute Ischemic InjurySverre E Aune, Daniel J Herr, Craig J Kutz, et al.
Aerospace Medicine and Human Performance|February 9, 2023
Aviation Decompression Sickness in Aerospace and Hyperbaric MedicineCraig J Kutz, Ian J Kirby, Ian R Grover, et al.
Bioorganic & Medicinal Chemistry|June 4, 2018
Corrigendum to "Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures" [Bioorg. Med. Chem. 23 (2015) 1601-1612]Shannon L Nowotarski, Boobalan Pachaiyappan, Steven L Holshouser, et al.
Bioorganic & Medicinal Chemistry|March 2, 2015
Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architecturesShannon L Nowotarski, Boobalan Pachaiyappan, Steven L Holshouser, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The Journal of Emergency Medicine|June 7, 2021
An Unexpected "Delivery" in the Emergency Department: Hydatidiform MoleCraig J Kutz, Allyson Kreshak
Aerospace Medicine and Human Performance|July 11, 2025
Expanding Ketamine Application for Treatment of Acute Suicidality in Long-Duration SpaceflightCraig J Kutz, Amit M Mistry, Charles H Dukes
Emergency Medicine Clinics of North America|June 26, 2024
Spaceflight EnvironmentSamantha A King, Craig J Kutz, Natacha G Chough
Medchemcomm|January 13, 2015
3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitorsCraig J Kutz, Steven L Holshouser, Ethan A Marrow, et al.
Frontiers in Neurology|July 16, 2015
Histone Deacetylases Exert Class-Specific Roles in Conditioning the Brain and Heart Against Acute Ischemic InjurySverre E Aune, Daniel J Herr, Craig J Kutz, et al.
Aerospace Medicine and Human Performance|February 9, 2023
Aviation Decompression Sickness in Aerospace and Hyperbaric MedicineCraig J Kutz, Ian J Kirby, Ian R Grover, et al.
Bioorganic & Medicinal Chemistry|June 4, 2018
Corrigendum to "Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures" [Bioorg. Med. Chem. 23 (2015) 1601-1612]Shannon L Nowotarski, Boobalan Pachaiyappan, Steven L Holshouser, et al.
Bioorganic & Medicinal Chemistry|March 2, 2015
Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architecturesShannon L Nowotarski, Boobalan Pachaiyappan, Steven L Holshouser, et al.
Pageof 1